Stocks Health care AURA
NASDAQ · Health careAura Biosciences, Inc. (AURA)
It posted a net loss of $136.9M. In fiscal 2025 capital spending exceeded operating cash flow by $85.2M. At September 30, 2026 it held $41.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Aura Biosciences, Inc.
- Net worth
- Aura Biosciences, Inc. has a market value (market cap) of $813M at the latest share price, and shareholders' equity of $287.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $84.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Aura Biosciences, Inc.'s next report is expected around March 29, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Aura Biosciences, Inc. does
Aura Biosciences, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker AURA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$106.2M | -$1.76 | -$85.2M |
| 2024 | n/a | -$86.9M | -$1.75 | -$81.1M |
| 2023 | n/a | -$76.4M | -$1.93 | -$64.6M |
| 2022 | n/a | -$58.8M | -$1.96 | -$55.7M |
| 2021 | n/a | -$35.3M | -$8.95 | -$34.5M |
| 2021 | n/a | -$22.2M | -$82.06 | -$25.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Aura Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- October 1, 2026Passive stake (5% or more) SCHEDULE 13G
- September 1, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
Insider trades
What the people running Aura Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 1, 2026 | Person JulieChief People Officer | Received as pay | 107,611 | - |
| September 1, 2026 | Hopkins Janet JillChief Medical Officer | Received as pay | 58,850 | - |
| September 1, 2026 | Elazzouzi AmySVP, Finance & PAO | Received as pay | 23,540 | - |
| September 1, 2026 | Abu-Absi SusanChief Operating Officer | Received as pay | 134,513 | - |
| September 1, 2026 | Kratz EricaChief Reg. & Quality Officer | Received as pay | 100,885 | - |
| July 7, 2026 | Bender JeremyDirector | Received as pay | 30,000 | - |
| July 1, 2026 | Kilroy ConorSee Remarks | Received as pay | 14,858 | - |
| June 16, 2026 | Gibney Anthony SSee Remarks | Sold | 12,824 | $82.3K |
Who owns AURA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Chen Yu13G, passive with 4 related filers | 9.9% | May 12, 2026 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 8.44% | August 12, 2026 |
| Suvretta Capital Management, LLC13G, passive with 2 related filers | 7.6% | August 13, 2025 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 13 related filers | 5.6% | August 14, 2026 |
| ForGrowth III PA B.V.13G, passive with 2 related filers | 5.1% | October 1, 2026 |
| BlackRock, Inc.13G, passive | 5.03% | October 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 146 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| TCG Crossover Management, LLC | 9,533,333 | new |
| Montanova Capital, LLC | 7,206,217 | +2,833,333 |
| Frazier Life Sciences Management, L.P. | 7,100,000 | +2,000,000 |
| Nantahala Capital Management, LLC | 5,902,060 | +3,784,363 |
| Long Focus Capital Management, LLC | 5,119,582 | +500,000 |
| BlackRock, Inc. | 4,707,674 | +1,121,034 |
| Adage Capital Partners GP, L.L.C. | 4,640,000 | -241,125 |
| Caligan Partners LP | 4,298,248 | +4,068,384 |
| Vanguard Capital Management LLC | 4,100,342 | +1,856,514 |
| Fcpm III Services B.V. | 4,053,775 | new |
| Orbimed Advisors LLC | 3,333,333 | new |
| Medicxi Ventures Management (Jersey) Ltd | 3,039,892 | 0 |
| Jupiter Topco LLC | 2,500,000 | new |
| RA Capital Management, L.P. | 2,500,000 | new |
| Balyasny Asset Management L.P. | 2,354,619 | +1,796,965 |
| Franklin Resources Inc | 2,072,726 | 0 |
| Geode Capital Management, LLC | 1,754,721 | +443,859 |
| Redmile Group, LLC | 1,666,667 | new |
| EcoR1 Capital, LLC | 1,666,667 | new |
| Trails Edge Capital Partners, LP | 1,443,333 | new |
Insiders
15 insiders reported holding 3,675,526 shares in total, about $28.8M at the last price.
| Holder | Shares |
|---|---|
| Holles Natalie C.See Remarks, Director | 1,153,962 |
| de los Pinos ElisabetSee Remarks, Director | 575,815 |
| Hopkins Janet JillChief Medical Officer | 380,190 |
| Gibney Anthony SSee Remarks | 265,354 |
| Plavsic MarkChief Technology Officer | 243,736 |
| Kilroy ConorSee Remarks | 232,693 |
| Johnson David MichaelDirector | 194,167 |
| Elazzouzi AmySVP, Finance & PAO | 143,600 |
| Abu-Absi SusanChief Operating Officer | 134,513 |
| Person JulieChief People Officer | 107,611 |
Questions about AURA
What does Aura Biosciences, Inc. do?
Aura Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as AURA. Its shares trade on NASDAQ under the ticker AURA.
What is Aura Biosciences, Inc.'s net worth?
Aura Biosciences, Inc. has a market value (market cap) of $813M at the latest share price, and shareholders' equity of $287.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Aura Biosciences, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $136.9M.
When did Aura Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Aura Biosciences, Inc.'s next earnings report?
Aura Biosciences, Inc.'s next report is expected around March 29, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AURA with
Follow AURA
Get an email when Aura Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Aura Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.